<DOC>
	<DOCNO>NCT00291408</DOCNO>
	<brief_summary>The purpose study compare histone acetyltransferase ( HAT ) histone deacetylase ( HDAC ) expressions activity induce sputum macrophage obtain patient moderate severe COPD age-matched normal non-smokers</brief_summary>
	<brief_title>Effect Symbicort HAT HDAC Sputum Macrophages COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Inclusion CriteriaHealthy nonsmoker Nonsmoking volunteer age 40 75 year ( age match COPD patient ) Normal spirometry ( normal FEV1/FVC ratio &gt; 70 % FEV1 &gt; 80 % predict ) Subjects able give inform consent Inclusion CriteriaCOPD patient ( stage IIIII accord GOLD guideline ) Current and/or exsmokers less 10 packyear smoke history age 40 75 year FEV1 great equal 30 % le 80 % predict ( upper value prostbronchodilator value ) FEV1/FVC &lt; 70 % Patients stable COPD Inhaled Corticosteroid ( ICS ) treatment , exist , must stop 2 week prior study treatment Longacting beta2agonists theophylline need stop least 3 day runin , anticholinergic allow throughout study The subject able give inform consent Exclusion CriteriaHealthy nonsmoker Pregnancy , breastfeed plan pregnancy study . Fertile woman use acceptable contraceptive measure , judge investigator Upper respiratory infection within last 4 week Subjects receive research medication within previous one month Subjects unable give inform consent Any psychiatric condition render patient unable understand nature , scope possible consequence study . Exclusion CriteriaCOPD patient Evidence asthma Bronchodilator reversibility &gt; 12 % Pregnancy , breastfeed plan pregnancy study . Fertile woman use acceptable contraceptive measure , judge investigator Patients oral steroid within 8 week prior screen visit . Patients already ICS consider unsafe ( judged Investigator ) stop treatment study period . Patients exacerbation require treatment oral steroid last 2 month prior screen visit . Upper respiratory infection within last 4 week Subjects receive research medication within previous one month Subjects unable give inform consent Any psychiatric condition render patient unable understand nature , scope possible consequence study Patients significant comorbidities judge investigator Any respiratory disease , consider investigator clinically significant</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>